Zenas BioPharma, Inc. ZBIO 深 滬
已收盤 02-06 16:00:00 美东时间
21.80
+0.790
+3.76%
華盛通- 最 高22.43
- 今 開21.48
- 成交量 86.43万股
- 最 低 20.91
- 昨 收 21.01
- 總市值 11.70亿
- 52周最高 44.60
- 市盈率 靜 --
- 換手率 1.61%
- 52周最低 6.11
- 委 比 36.05%
- 總股本 5367.92万
- 歷史最高 44.60
- 量 比 1.03
- 振 幅 7.23%
- 歷史最低 5.83
- 每 手 1
- 風險率 10.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 私人航空公司UP单日暴涨46%！One Stop大涨29%，获美军预生产订单
私人航空公司UP单日暴涨46%！One Stop股价涨29%，获美军预生产订单；BIOA涨逾27%，核心在研药获突破进展>>
01-13 17:24
Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
01-10 21:31
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Morgan Stanley Downgrades Zenas BioPharma to Equal-Weight, Lowers Price Target to $19
Morgan Stanley analyst Judah Frommer downgrades Zenas BioPharma (NASDAQ:ZBIO) from Overweight to Equal-Weight and lowers the price target from $37 to $19.
01-06 23:44
Why Zenas BioPharma's Selloff Was Structurally Inevitable
Zenas BioPharma (NASDAQ:ZBIO) shares fell more than 50% in the last trading ses...
01-06 20:38
Zenas BioPharma Announces Results From Phase 3 INDIGO Trial Of Obexelimab In Immunoglobulin G4-Related Disease
- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare -- Obexelimab also met and demonstrated statistically significant
01-05 20:09
美股周涨跌榜 | Sable Offshore涨超37%，获重启加州管道的批准；百度涨超20%
Sable Offshore涨超37%，获重启加州管道的批准；Ondas Holdings涨近30%，获1000万美元新自主系统订单；百度涨超20%，拟分拆昆仑芯于港交所上市>>
01-04 10:38
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.
2025-12-22 21:40
Evercore ISI Group Initiates Coverage On Zenas BioPharma with Outperform Rating, Announces Price Target of $55
Evercore ISI Group analyst Cory Kasimov initiates coverage on Zenas BioPharma (NASDAQ:ZBIO) with a Outperform rating and announces Price Target of $55.
2025-11-26 21:14
